Senate Special Committee on Aging Calls Business Meeting to Initiate Contempt Proceedings Against Valeant CEO Michael Pearson
Senators Susan Collins and Claire McCaskill take action after Pearson fails to obey subpoena for deposition into Committee’s drug pricing investigation
WASHINGTON, D.C. – Senate Special Committee on Aging Chairman Susan Collins and Ranking Member Claire McCaskill today scheduled a Business Meeting of the Committee to initiate contempt proceedings against Valeant Chief Executive Officer Michael Pearson, who today failed to appear for a deposition related to the Committee’s ongoing investigation into pharmaceutical drug pricing.
“Michael Pearson was under subpoena to appear for a deposition today related to the Senate Special Committee on Aging’s drug pricing investigation, and he did not comply with that subpoena,” said Collins and McCaskill in a joint statement. “His actions and those of Valeant are central to the investigation pursued by this Committee. Therefore, it is our intent to initiate contempt proceedings against Mr. Pearson.”
The Senate Special Committee on Aging has held two previous hearings during their investigation. To date, the hearings have included experts in drug pricing, medical providers, government officials, company executives, and pharmaceutical investors.
Pearson remains under subpoena to appear before the Committee for a hearing on April 27.